Life Sciences Archives - Becker's Hospital Review

FDA panel: Ease restrictions on 6 peptides | Where the GLP-1 compounding fight stands | FDA OKs 1st Tylenol pain drug | FDA issues 17 peptide guidances | 6 GLP-1 findings to know

Also inside: a nationwide recall on thyroid medication. July 29, 2026 1. FDA panel recommends easing restrictions on 6 of 7 peptides: What to know Full story 2. Where the GLP-1 compounding fight stands: 5 things to know Full story…

The hidden cost of GLP-1s | FDA approves 1st gene-targeting cancer drug | GLP-1 compounders find loophole | New cholesterol guideline adds 21.5M statin candidates | Brand-name drug denials surge

FDA approves gene therapy for cancer, GLP-1 fallout and a new 340B reform push. July 22, 2026 1. FDA approves gene-targeting cancer drug Full story 2. The hidden cost of the GLP-1 boom: 5 notes Full story 3. How CFOs…

FDA approves 1st on-body cancer drug | What to know about the peptide boom | Cyclospora outbreak surpasses 2,600 cases | 6 things to know as GLP-1 use hits record high | Novo eyes GLP-1 implant as next bet

Plus: a wearable drug approval, a fast-moving outbreak and the latest in the obesity drug race. July 15, 2026 1. FDA approves 1st on-body cancer drug Full story 2. The peptide boom: What healthcare leaders should know Full story 3.…

New HHS program aims to speed clinical trials | Oral GLP-1 delivers 11% weight loss | 11K bottles of blood pressure medication recalled | Tampa General sues Eli Lilly | 5 new drugs in shortage

Clinical trial reform, GLP-1 results, a medication recall and new drug shortages. July 8, 2026 1. HHS launches Operation TrailBlazer to speed up clinical trials: 5 notes Full story 2. Oral GLP-1 delivers up to 11.3% weight loss: 4 study…

Amgen recalls 934K+ bottles of heart, kidney drugs | Cancer drug shortages raise rationing concerns | AstraZeneca to pay $34M over Medicaid kickbacks | Immunotherapy approvals dropped 40% last year | GLP-1s linked to slower biological aging

Drug recalls and shortages mount, plus a new case for GLP-1s. July 1, 2026 1. Amgen recalls 934K+ bottles of heart, kidney drugs Full story 2. AstraZeneca to pay Texas $34M over alleged Medicaid kickbacks Full story 3. Central Florida…

Ebola cases jump 38% in 1 week | FDA approves 1st single-dose flu drug | 8 GLP-1 findings to know | 46 highest-paid healthcare CEOs | GLP-1s may improve fertility

Ebola outbreak updates, a drug milestone and the latest on GLP-1s. June 24, 2026 1. FDA approves 1st single-dose generic flu drug Full story 2. Ebola outbreak is 3x larger at 4 weeks than any before: 6 updates Full story 3. NYU…

Lilly wins injunction in $200M fraud lawsuit | What next-gen GLP-1s are trying to solve | Nonprofit secures access to experimental cancer drug | Lilly's oral GLP-1 outperforms rival in trial | Inside the escalating 340B rebate battle

From fraud to breakthroughs: the week’s biggest life sciences moves. June 17, 2026 1. Court grants Lilly injunction in lawsuit alleging $200M fraud scheme Full story 2. Next-gen GLP-1s target 3 key limitations: Report Full story 3. Precision genomics at…

FDA clears 1st AI drug development tool | The new cancer pill getting leaders' attention | 7 conditions GLP-1s treat beyond weight loss | Study flags infection risk with antibody therapies | Anthropic AI model cuts drug design time

AI drug tools, a new cancer pill, GLP-1 surprises and an antibody caution. June 10, 2026 1. What leaders need to know about the breakthrough pancreatic cancer pill Full story 2. FDA accepts letter of intent for 1st AI drug development tool Full…

FDA approves 1st COVID pill | Mounjaro beats rival GLP-1s in trial | Cancer drug shows efficacy across 6 tumor types | GLP-1s may cut breast cancer risk | Lilly gives hospitals 340B ultimatum

GLP-1 and cancer breakthroughs, plus a pharma showdown with hospitals. June 3, 2026 1. FDA approves 1st oral COVID-19 prevention drug Full story 2. Mounjaro outperforms other GLP-1s in early Type 2 diabetes treatment: Study Full story 3. Is your…

GLP-1s linked to lower cancer incidence | Parkinson's drug halted after trial fail | FDA approves 1st chronic HDV treatment | Can Epic get any bigger? | 3 drug safety fronts to watch

Cancer prevention, a midstage trial failure and an FDA first. May 27, 2026 1. GLP-1s and cancer outcomes: What new research shows Full story 2. Parkinson’s drug development halted after midstage trial failure Full story 3. $20K–$60K per infection: Why…

Join the 500,000+ healthcare executives who start their day with Becker’s